Norepinephrine / Vasopressin Combination for Resuscitation in Septic Shock
Primary Purpose
Septic Shock, Acute Kidney Injury
Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
norepinephrine / Vasopressin
Sponsored by
About this trial
This is an interventional treatment trial for Septic Shock
Eligibility Criteria
Inclusion Criteria:
- Age > 18 years of both sex
Exclusion Criteria
- Patients with renal impairment (Creatinine>2mg/dl)
- Sever Heart Disease (ischemic/valvular)
- Peripheral vascular disease (e.g. Raynaud's phenomenon)
Sites / Locations
- Hanaa El Gendy
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
NE
NE/VP
Arm Description
patients received IV Norepinephrine infusion starting with (0.1mcg/kg/min)
patients received IV Norepinephrine infusion (Starting with (0.1 mcg/kg/min). +Vasopressin infusion at the rate of (0.03 unit/min)
Outcomes
Primary Outcome Measures
Lactate Level Lactate level • (central venous oxygen saturation)SVO2
mmol/L
Scvo2
Secondary Outcome Measures
NGAL, NGAL NGAL
ng/ml
Mortality
28 days mortality
CRP
mg/dl
Full Information
NCT ID
NCT04302584
First Posted
February 28, 2020
Last Updated
September 4, 2020
Sponsor
Ain Shams University
1. Study Identification
Unique Protocol Identification Number
NCT04302584
Brief Title
Norepinephrine / Vasopressin Combination for Resuscitation in Septic Shock
Official Title
Comparison of Between Norepinephrine Alone Versus Norepinephrine / Vasopressin Combination for Resuscitation in Septic Shock
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
January 1, 2018 (Actual)
Primary Completion Date
January 5, 2019 (Actual)
Study Completion Date
January 6, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ain Shams University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Although norepinephrine is commonly used and is the recommended agent for the treatment of hypotension in volume-resuscitated hyperdynamic septic shock, Low doses of vasopressin may be added to norepinephrine to maintain arterial blood pressure in refractory septic shock and to decrease exposure to norepinephrine. The aim of the work is to compare the effect of norepinephrine alone and Norepinephrine/vasopressin combination on hemodynamics and tissue perfusion in septic shock patients.
Detailed Description
Study which was performed on 90 adult of either sex in intensive care unit who developed septic shock.45 patients in each group according to the drugs used, by the single blind technique as the treating physician only is aware of the drugs used.
Group 1: patients received IV Norepinephrine infusion starting with (0.1mcg/kg/min).
Group 2: patients received IV Norepinephrine infusion (Starting with (0.1 mcg/kg/min). +Vasopressin infusion at the rate of (0.03 unit/min).
A comparison was done between both groups as regard:Hemodynamics,Tissue perfusion, C-Reactive Protein (mg/L) ,WBC, UREA (mg/dL),CREATININE (mg/dl), NGAL (Neutrophil gelatinase associated Lipocalin) (ng/ml). Comparison was done at baseline, then every 6 hours for 48 h as regard hemodynamics and tissue perfusion, and at base line then, 24 h and 48 h as regard sepsis biomarkers and renal biomarkers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock, Acute Kidney Injury
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
90 (Actual)
8. Arms, Groups, and Interventions
Arm Title
NE
Arm Type
Active Comparator
Arm Description
patients received IV Norepinephrine infusion starting with (0.1mcg/kg/min)
Arm Title
NE/VP
Arm Type
Active Comparator
Arm Description
patients received IV Norepinephrine infusion (Starting with (0.1 mcg/kg/min). +Vasopressin infusion at the rate of (0.03 unit/min)
Intervention Type
Drug
Intervention Name(s)
norepinephrine / Vasopressin
Other Intervention Name(s)
norepinephrine
Intervention Description
• The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.
Primary Outcome Measure Information:
Title
Lactate Level Lactate level • (central venous oxygen saturation)SVO2
Description
mmol/L
Time Frame
48 hours
Title
Scvo2
Time Frame
48 hours
Secondary Outcome Measure Information:
Title
NGAL, NGAL NGAL
Description
ng/ml
Time Frame
48 hours
Title
Mortality
Description
28 days mortality
Time Frame
28 days
Title
CRP
Description
mg/dl
Time Frame
48 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age > 18 years of both sex
Exclusion Criteria
Patients with renal impairment (Creatinine>2mg/dl)
Sever Heart Disease (ischemic/valvular)
Peripheral vascular disease (e.g. Raynaud's phenomenon)
Facility Information:
Facility Name
Hanaa El Gendy
City
Cairo
State/Province
Ain Shams University Specialized Hospital
Country
Egypt
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Norepinephrine / Vasopressin Combination for Resuscitation in Septic Shock
We'll reach out to this number within 24 hrs